NCT06482489Recrutement en cours
Accurate Prostate Cancer Following Using Low-Field MRI (Low-PRISM)
Résumé
This study compares the effectiveness of low-field MRI (0.55T) with high-field MRI (3T) in prostate cancer screening and image quality. It consists of three phases: optimizing the low-field MRI protocol with healthy volunteers, evaluating image quality in patients with metallic artifacts (like hip prostheses), and assessing low-field MRI in patients with suspicious prostate lesions found on high-field MRI.
Critères d'inclusion
Work Package1 (WP): 0.55T MRI Protocol Development • Healthy male volunteers aged 18 and above. • Agree to be contacted for incidental findings • Signed informed consent WP2: 0.55T Prostate MRI with patients with metallic implant(s) • Adult men (≥18 y.o) with 3T MRI reported as sub-diagnostic due to metallic implants • Signed informed Consent WP3: 0.55T Prostate MRI with patients with suspicious lesion(s) • Adult men (≥18 y.o) • PI-RADS 4/5 lesions detected on 3T MRI, schedules for targeted biopsy • Signed informed consent
Critères d'exclusion
WP1: 0.55T MRI Protocol Development • Individuals with a history of prostate cancer • MR Contraindications as listed in the MR Safety Screening form WP2: 0.55T Prostate MRI with patients with metallic implant(s) • Contraindications as per MD instructions • Any condition making the patient unsuitable for the study • Refusal to be notified in case of incidental finding on the examination WP3: 0.55T Prostate MRI with patients with suspicious lesion(s) • Individuals with a history of prostate cancer. • Contraindications as per MD instructions • Any condition making the patient unsuitable for the study • Refusal to be notified in case of incidental finding on the examination
Contacts
Les coordonnées de l'équipe de l'essai s'affichent sur demande.
Voir la fiche officielle de l'essai- Statut
- Recrutement en cours
- Phase
- —
- Type d'étude
- Observationnelle
- Pays
- Suisse
- Promoteur
- University of Lausanne Hospitals(Autre)
- N° de protocole
- 2024-D0049
- Pathologies
- Prostate Cancer
- Interventions
- Dispositif
Traitements évalués
- Siemens Magnetom Free.Max 0.55T (Siemens Healthineers, Erlangen, Germany).
Lieux · 1
- Lausanne, SuisseLausanne University HospitalRecrute dans ce centre
Au total, dans le monde, le seul centre listé au registre recrute.
Statut par centre selon le registre ClinicalTrials.gov (dernière mise à jour publiée : 3 avril 2025).
Ce statut peut avoir changé et ne dit rien de votre éligibilité : avant toute démarche, vérifiez avec votre oncologue ou le centre.
Voir aussi
Autres versions
Ces résultats sont indicatifs et ne remplacent pas un avis médical — à discuter avec votre médecin.